# A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

> **NCT04644315** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 1 (actual)

## Conditions studied

- Neoplasms
- Colorectal Neoplasms
- Melanoma
- Pancreatic Neoplasms
- Sarcoma
- Ovarian Neoplasms
- Brain Neoplasms
- Thyroid Neoplasms
- Neuroendocrine Tumors
- Cholangiocarcinoma
- Salivary Gland Neoplasms
- Head and Neck Neoplasms
- Thyroid Cancer, Papillary
- Lymphoma, Large-Cell, Anaplastic
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Respiratory Tract Diseases
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Central Nervous System

## Interventions

- **DRUG:** Alectinib

## Key facts

- **NCT ID:** NCT04644315
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-24
- **Primary completion:** 2022-05-16
- **Final completion:** 2022-05-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The data from this study is no longer needed.
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04644315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04644315, "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04644315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*